By PPN News Staff
Grifols introduced HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B (HBIG) postexposure prophylaxis.
The new FDA-approved formulation uses a unique caprylate chromatography process, which significantly reduces procoagulant activity and immunoglobulin G aggregates. It also includes FDA labeling for the capacity to remove pathogenic prions.
HyperHEP B is the newest version of Grifols’ current HBIG, HyperHEP B S/D.